Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour

被引：6

作者：

Grabellus, Florian

Ebeling, Peter

Worm, Karl

Sheu, Sien-Yi

Antoch, Gerald

Frilling, Andrea

Schmid, Kurt W.

机构：

[1] Univ Hosp Essen, Dept Pathol & Neuropathol, D-45122 Essen, Germany

[2] Univ Hosp Essen, Dept Internal Med Canc Res, D-45122 Essen, Germany

[3] Univ Hosp Essen, Dept Diagnost & Intervent Radiol, D-45122 Essen, Germany

[4] Univ Hosp Essen, Dept Gen Surg & Transplantat, D-45122 Essen, Germany

来源：

GUT | 2007年 / 56卷 / 07期

关键词：

D O I：

10.1136/gut.2006.115923

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1025 / 1026

页数：2

共 9 条

[1] Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].

Antonescu, CR ;

Besmer, P ;

Guo, TH ;

Arkun, K ;

Hom, G ;

Koryotowski, B ;

Leversha, MA ;

Jeffrey, PD ;

Desantis, D ;

Singer, S ;

Brennan, MF ;

Maki, RG ;

DeMatteo, RP .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190

[2]

BENJAMIN R, 2006, OR PRES 641 CTOS 12

[3] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].

Heinrich, MC ;

Corless, CL ;

Demetri, GD ;

Blanke, CD ;

von Mehren, M ;

Joensuu, H ;

McGreevey, LS ;

Chen, CJ ;

Van den Abbeele, AD ;

Druker, BJ ;

Kiese, B ;

Eisenberg, B ;

Roberts, PJ ;

Singer, S ;

Fletcher, CDM ;

Silberman, S ;

Dimitrijevic, S ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349

[4] Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].

Hirota, S ;

Isozaki, K ;

Moriyama, Y ;

Hashimoto, K ;

Nishida, T ;

Ishiguro, S ;

Kawano, K ;

Hanada, M ;

Kurata, A ;

Takeda, M ;

Tunio, GM ;

Matsuzawa, Y ;

Kanakura, Y ;

Shinomura, Y ;

Kitamura, Y .

SCIENCE, 1998, 279 (5350) :577-580

[5]

Kindblom LG, 1998, AM J PATHOL, V152, P1259

[6] Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate [J].

Prenen, H ;

Cools, J ;

Mentens, N ;

Folens, C ;

Sciot, R ;

Schöffski, P ;

Van Oosterom, A ;

Marynen, P ;

Debiec-Rychter, M .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2622-2627

[7] Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies [J].

Schittenhelm, MM ;

Shiraga, S ;

Schroeder, A ;

Corbin, AS ;

Griffith, D ;

Lee, FY ;

Bokemeyer, C ;

Deininger, MWN ;

Druker, BJ ;

Heinrich, MC .

CANCER RESEARCH, 2006, 66 (01) :473-481

[8] Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate [J].

Wardelmann, E ;

Merkelbach-Bruse, S ;

Pauls, K ;

Thomas, N ;

Schildhaus, HU ;

Heinicke, T ;

Speidel, N ;

Pietsch, T ;

Buettner, R ;

Pink, D ;

Reichardt, P ;

Hohenberger, P .

CLINICAL CANCER RESEARCH, 2006, 12 (06) :1743-1749

[9] Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations [J].

Wardelmann, E ;

Thomas, N ;

Merkelbach-Bruse, S ;

Pauls, K ;

Speidel, N ;

Büttner, R ;

Bihl, H ;

Leutner, CC ;

Heinicke, T ;

Hohenberger, P .

LANCET ONCOLOGY, 2005, 6 (04) :249-251

← 1 →